Many practicing physicians have recently received "Important drug warning and new prescribing information" from Amgen and Ortho Biotech with regard to formulations of erythro poietin. Apparently, patients receiving these agents have an increased incidence of throm boses and thromboembolic events (Bohlius J et al. [2006] J Natl Cancer Inst 98: 708-714). I suggest that a possible cause of some of these problems is altered hematopoietic stemcell differentiation, favoring erythrocytic and thrombo cytic pathways at the expense of granulopoiesis following bleeding or erythropoietin adminis tration. This preferential erythropoietic differen tiation was first reported in mice almost 40 years ago (Hellman S and Grate HE [1967] Nature 216: 65-66). This competition of the differentiation pathways argued strongly for the functional importance of a common hematopoietic stem cell. In these experiments, transplanted bone marrow hematopoietic progenitor cells prefer entially differentiated towards the erythrocytic pathway when administered into wholebody irradiated syngeneic recipients that had been bled or given erythropoietin. Hematopoietic stemcell differentiation favoring erythropoiesis occurred at the expense of a concomitant diminished granulo cyte response to bacterial endotoxin. This pref erential differentiation toward the erythrocytic pathway is accompanied by increased platelet production, which might be the cause of the increased thromboembolic events seen with the clinical use of erythropoietin (Goodman R et al. [1977] Blood 49: 253-261). The decrease in granulocyte production associated with increased erythrocytic stimulation may lead to infectious complications, which should be looked for in patients treated with erythropoietin, espe cially those receiving chemotherapy or extensive radiation therapy.
Another complication reported in patients with cancer treated with erythropoietin was increased tumor growth (Henke M [2003] Lancet 362: 1255-1260), which might be because of a better oxygen supply to the tumor. The increased tumor proliferation, however, might also be attributable to erythropoietin directly stimulating tumor cells.
In this instance, the term erythropoietin does not fully describe the activity of the agent. Such naming of agents on the basis of their first observed function may restrict our thinking with regard to the properties of the agent. The major oncologicallyrelated effects of platelet derived growth factor relate to its angiogenic and tumor cell proliferation stimulating activi ties rather than to platelets. Other examples of substances with more protean activities that are named for their first described func tion include tumor necrosis factor and the heat shock proteins, all of which have many actions beyond those described by their names.
There are at least two lessons to be learned from these clinical results. First, it pays to review animal experiments before embarking on human administration, even if the experi ments are in the old literature. While there are considerable speciesrelated differences, one of the purposes of doing experiments in animals is to provide guidance in determining both the uses and possible untoward effects of new therapies. The older literature may be more difficult to access, but that does not limit its relevance. Second, what's in a name? The term 'erythropoietin' may not describe the universe of the activities of this biologically important substance. While clearly there were unintended consequences of erythro poietin use, they should not have been completely unexpected. 
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